Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update

Biodesix, Inc. (NASDAQ:BDSX) was the target of a large drop in short interest in December. As of December 31st, there was short interest totalling 836,600 shares, a drop of 7.4% from the December 15th total of 903,100 shares. Based on an average daily volume of 420,900 shares, the short-interest ratio is currently 2.0 days.

Insider Transactions at Biodesix

In related news, Chairman John Patience acquired 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were acquired at an average price of $1.38 per share, with a total value of $103,500.00. Following the completion of the purchase, the chairman now directly owns 2,153,298 shares in the company, valued at approximately $2,971,551.24. The trade was a 3.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack W. Schuler bought 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was purchased at an average cost of $1.17 per share, with a total value of $234,000.00. Following the purchase, the director now directly owns 31,094,935 shares in the company, valued at $36,381,073.95. The trade was a 0.65 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 315,000 shares of company stock valued at $393,500 in the last ninety days. Corporate insiders own 69.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new stake in shares of Biodesix in the third quarter worth approximately $10,849,000. Barclays PLC boosted its holdings in shares of Biodesix by 1,140.5% in the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Biodesix by 50.7% during the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after buying an additional 270,724 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of Biodesix during the 3rd quarter worth $262,000. Finally, Perkins Capital Management Inc. increased its holdings in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after buying an additional 310,000 shares during the last quarter. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Stock Up 0.9 %

Shares of NASDAQ BDSX opened at $1.15 on Monday. The firm has a market cap of $167.29 million, a P/E ratio of -2.95 and a beta of 1.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix has a 1 year low of $1.09 and a 1 year high of $2.21. The firm’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.57.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Friday, November 1st. The company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The business had revenue of $18.15 million during the quarter, compared to the consensus estimate of $18.45 million. During the same quarter in the previous year, the business earned ($0.12) earnings per share. As a group, sell-side analysts anticipate that Biodesix will post -0.35 earnings per share for the current year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.